Cavion LLC Expands Drug Discovery Program
Thursday, October 15, 2015
Cavion LLC has hired Thomas Richardson, PhD, as Director of Chemistry Discovery and Development. Dr. Richardson will work toward expanding the company’s platform of novel T-type calcium channel inhibitors through drug discovery and assessing in-licensing opportunities.
Dr. Richardson received his doctorate in Organic Chemistry from The Ohio State University and brings to Cavion fifteen years’ experience as a medicinal chemist in the pharmaceutical industry, most recently serving as Research Investigator in the Medicinal Chemistry Division of SCYNEXIS, Inc.
“I look forward to working with Dr. Richardson to identify and develop novel T-type calcium channel inhibitors to move into, and through, the discovery process,” stated Cavion President and CEO Andrew Krouse. “These new compounds will complement Cavion’s clinical stage assets for oncology and neurology.”
Cavion also expanded its staff by hiring Allison de Almeida, a graduate of The Pennsylvania State University, as Analyst and Evan Newbold, a graduate of Lafayette College, as Science Research Analyst.